What is Compass Therapeutics?
Headquartered in Boston, Massachusetts, Compass Therapeutics is a clinical-stage biopharmaceutical entity dedicated to the discovery and development of novel antibody-based treatments. The company's research focus centers on modulating critical signaling pathways, such as the Delta-like ligand 4 and vascular endothelial growth factor A, which are essential for tumor vascularization. Furthermore, the firm is advancing candidates like CTX-471 and CTX-8371, which target CD137 and PD-1/PD-L1 pathways, respectively. By integrating advanced immunology with precision medicine, Compass Therapeutics aims to redefine therapeutic standards for patients with limited treatment options in oncology.
How much funding has Compass Therapeutics raised?
Compass Therapeutics has raised a total of $213.8M across 3 funding rounds:
Private Equity
$21.8M
Series A
$132M
Share Placement
$60M
Private Equity (2017): $21.8M, investors not publicly disclosed
Series A (2018): $132M led by OrbiMed, Cowen Healthcare Investments, Alexandria Venture Investments, Ulysses Diversified Holdings, Borealis Ventures, Thiel Capital, Biomed Realty Ventures, Biomatics Capital, and F-Prime Capital Partners
Share Placement (2020): $60M supported by Olivia Ventures
Key Investors in Compass Therapeutics
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms to support innovation at various development stages.
Cowen Healthcare Investments
Cowen is an independent financial services firm providing comprehensive investment banking, research, and investment management services with a deep history in the financial markets.
Alexandria Venture Investments
Alexandria Venture Investments is the strategic venture arm of a prominent real estate investment trust, focusing on the life sciences industry and providing essential infrastructure for research and development.
What's next for Compass Therapeutics?
With the recent influx of capital, Compass Therapeutics is well-positioned to accelerate its clinical trial programs and expand its research capabilities. The strategic focus will likely remain on the maturation of its lead product candidates, CTX-009 and CTX-471, through rigorous human clinical testing. As the company navigates the complexities of the regulatory environment, the emphasis will shift toward demonstrating efficacy and safety profiles that justify further commercialization efforts. Future growth will be contingent upon the firm's ability to maintain its competitive edge in the rapidly evolving biopharmaceutical market, potentially through continued strategic partnerships and the optimization of its proprietary antibody platform.
See full Compass Therapeutics company page
